Profile data is unavailable for this security.
About the company
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
- Revenue in USD (TTM)0.00
- Net income in USD-11.35m
- Incorporated1973
- Employees2.00
- LocationGT Biopharma Inc315 MONTGOMERY STREET, 10TH FLOORSAN FRANCISCO 94104United StatesUSA
- Phone+1 (310) 551-4020
- Fax+1 (302) 655-5049
- Websitehttps://www.gtbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.20m | 3.25m | 8.00 | -- | 0.4796 | -- | -- | -10.29 | -10.29 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -123.53 | -- | -147.27 | -- | -- | -- | -- | -- | -- | -4.32 | 0.5076 | -- | -- | -- | -112.71 | -- | -- | -- |
| Evoke Pharma Inc | 7.53m | -6.53m | 3.31m | 4.00 | -- | 1.24 | -- | 0.4404 | -16.23 | -16.23 | 11.24 | 3.63 | 0.7128 | 0.4307 | 4.97 | 1,881,428.00 | -61.83 | -100.48 | -136.53 | -151.10 | 96.97 | -- | -86.75 | -480.52 | 1.22 | -19.91 | 0.6523 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Sentient Brands Holdings Inc | 0.00 | -954.07k | 3.35m | 2.00 | -- | -- | -- | -- | -0.0164 | -0.0164 | 0.00 | -0.0307 | 0.00 | 0.00 | -- | 0.00 | -460.67 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0015 | -2.50 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
| Sonoma Pharmaceuticals Inc | 12.70m | -4.56m | 3.55m | 172.00 | -- | 0.6609 | -- | 0.2795 | -10.07 | -10.07 | 20.98 | 5.24 | 0.859 | 2.91 | 4.47 | 73,831.40 | -30.85 | -29.36 | -41.88 | -40.65 | 38.17 | 38.00 | -35.91 | -30.93 | 2.47 | -- | 0.0394 | -- | -4.05 | -7.66 | 6.13 | -- | -29.84 | -- |
| Sunshine Biopharma Inc | 30.48m | -3.68m | 3.55m | 44.00 | -- | 0.1576 | -- | 0.1166 | -194.01 | -194.01 | 1,017.85 | 20.07 | 1.06 | 3.33 | 10.19 | 692,772.50 | -12.75 | -101.52 | -15.41 | -137.04 | 30.41 | 35.47 | -12.07 | -165.33 | 3.26 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
| China Pharma Holdings Inc | 6.25m | -4.40m | 3.75m | 231.00 | -- | 0.5067 | -- | 0.6008 | -0.6254 | -0.6254 | 0.6379 | 0.4317 | 0.417 | 2.34 | 23.57 | 27,047.32 | -29.39 | -29.66 | -59.89 | -55.25 | -25.89 | 6.47 | -70.48 | -73.09 | 0.2449 | -21.22 | 0.3494 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 4.24m | -- | 0.0236 | 0.0051 | 1.16 | 0.3981 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -10.22m | 4.43m | 13.00 | -- | 0.6477 | -- | -- | -5.36 | -5.36 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -115.58 | -84.35 | -133.48 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0016 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| GT Biopharma Inc | 0.00 | -11.35m | 4.58m | 2.00 | -- | 0.8317 | -- | -- | -7.72 | -7.72 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -82.84 | -205.36 | -120.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -3.45m | 4.66m | 3.00 | -- | 0.6495 | -- | 64.67 | -1.16 | -1.18 | 0.0242 | 1.60 | 0.0079 | -- | -- | 24,040.00 | -37.69 | -24.90 | -43.50 | -26.39 | 91.90 | 82.79 | -4,777.02 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
| Stemtech Corp | 5.37m | -5.11m | 4.83m | 45.00 | -- | -- | -- | 0.8998 | -0.0518 | -0.0518 | 0.0529 | -0.0359 | 1.33 | 8.39 | 42.31 | -- | -126.26 | -- | -- | -- | 77.87 | -- | -95.16 | -- | 0.065 | -2.59 | -- | -- | 7.94 | -- | 36.45 | -- | -- | -- |
| CYANOTECH CORP | 23.82m | -5.10m | 4.87m | 77.00 | -- | 0.4563 | -- | 0.2045 | -0.7549 | -0.7549 | 3.56 | 1.53 | 0.8895 | 2.05 | 12.12 | 309,389.60 | -19.04 | -3.46 | -29.60 | -4.46 | 24.72 | 34.54 | -21.41 | -3.58 | 0.3354 | -6.61 | 0.377 | -- | -0.4616 | -5.24 | -53.11 | -- | -6.42 | -- |
| AgriFORCE Growing Systems Ltd | 57.60k | -15.05m | 5.16m | 7.00 | -- | 0.4074 | -- | 89.59 | -5.81 | -5.81 | 0.0037 | 0.1343 | 0.0034 | -- | 1.21 | 8,228.57 | -88.79 | -78.95 | -124.14 | -109.86 | 17.86 | -- | -26,121.49 | -243,182.50 | 1.24 | -1.28 | 0.0789 | -- | -- | -- | 8.85 | -- | 48.61 | -- |
| Titan Pharmaceuticals Inc | 4.00k | -5.46m | 5.17m | 4.00 | -- | 1.30 | -- | 1,293.64 | -6.59 | -6.59 | 0.0049 | 4.37 | 0.0016 | -- | 0.1702 | 1,000.00 | -211.58 | -96.80 | -368.99 | -156.65 | -- | -- | -136,525.00 | -406.26 | -- | -309.96 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Sonnet Biotherapeutics Holdings Inc | 55.89k | -7.99m | 5.20m | 12.00 | -- | 1.99 | -- | 93.08 | -3.02 | -3.02 | 0.0144 | 0.5017 | 0.0071 | -- | 0.0881 | 4,657.50 | -100.88 | -- | -255.30 | -- | -- | -- | -14,287.67 | -- | -- | -331.07 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to GT Biopharma Inc's reporting currency: US Dollar USD
56.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deka Investment GmbHas of 30 Jun 2024 | 978.36k | 43.79% |
| Bristol Capital Advisors LLCas of 23 May 2024 | 190.00k | 8.50% |
| BMO Asset Management Corp.as of 30 Jun 2024 | 29.87k | 1.34% |
| G1 Execution Services LLCas of 30 Jun 2024 | 18.98k | 0.85% |
| Geode Capital Management LLCas of 30 Jun 2024 | 11.18k | 0.50% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 10.50k | 0.47% |
| Wells Fargo Advisors Financial Network LLCas of 30 Jun 2024 | 10.01k | 0.45% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 9.77k | 0.44% |
| UBS Securities LLCas of 30 Jun 2024 | 8.98k | 0.40% |
| Tower Research Capital LLCas of 30 Jun 2024 | 2.17k | 0.10% |
More ▼
Data from 30 Jun 2024 - 26 Aug 2024Source: FactSet Research Systems Inc.
